statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the business's stock in a transaction on Thursday, March 28th. The shares were acquired at...

Gain Therapeutics, Inc. (NASDAQ:GANX) Director Jeffrey Scott Riley Acquires 30,000 Shares

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 156,700 shares, an...

Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)

Gain Therapeutics (GANX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson's Treatment and Solid Financial Outlook

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Gain Therapeutics appoints Jonas Hannestad as CMO

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ( Gain , or the Company ), a clinical-stage biotechnology company leading the discovery and development of...

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ( Gain , or the Company ), a clinical-stage biotechnology company leading the discovery and development of...

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Gain Therapeutics GAAP EPS of -$1.71 misses by $0.14, revenue of $0.05M misses by $0.25M...

Gain Therapeutics GAAP EPS of -$1.71 misses by $0.14, revenue of $0.05M misses by $0.25M

Gain Therapeutics: Q4 Earnings Insights

Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb...

Gain Therapeutics to Present at Public Ventures Discovery Day

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Volume	96,022.00
52-Wk High	$5.65
52-Wk Low	$2.00

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.31	--	--	N/A
Q4'23	-$0.32	-$0.29	7.94%	BEAT
Q3'23	-$0.45	-$0.37	17.04%	BEAT
Q2'23	-$0.31	-$0.62	-101.36%	MISSED
Q1'23	-$0.39	-$0.43	-9.15%	MISSED

GANX Gain Therapeutics Inc

About

Feed

News

Earnings

Fundamentals